ID Stewardship

JUNE 6, 2023

In this article, ChatGPT provides witty insights into the cross-roads of artificial intelligence and infectious diseases. Welcome to a contagiously captivating conversation with ChatGPT, the one and only “Infectious Intellect.” So, dear students, embrace the AI ally in your quest for infectious knowledge.

Immunity 91

Immunity Immunization 91

ID Stewardship

AUGUST 1, 2023

In this article, a pharmacist from Turkey with advanced training in the area of infectious diseases provides insights on antimicrobial stewardship in Turkey. Clinical pharmacy in Turkey is still developing. Formal postgraduate training started in 2018 (clinical pharmacy specialization training). Interviewer: Timothy P.

Hospitals 84

Hospitals Community Pharmacies Dosage Communication 84

European Pharmaceutical Review

OCTOBER 4, 2023

This follows the WHO’s recommendation of the RTS,S/AS01 vaccine for the disease in 2021. The World Health Organization ( WHO ) has recommended a new vaccine, R21/Matrix-M, to prevent malaria in children. The R21 vaccine is the second malaria vaccine recommended by WHO.

Vaccines 102

Vaccines 102

European Pharmaceutical Review

AUGUST 21, 2023

According to a market report , the global RNA therapy clinical trials market is anticipated to reach $3.5 This has therefore led to a rise in the number of RNA clinical trials being conducted. This has also resulted in the pharmaceutical industry investigating RNA as a target to treat other infectious diseases and oncology indications.

Vaccines 92

Vaccines 92

Express Pharma

DECEMBER 26, 2023

Ractigen Therapeutics, headquartered in China, submitted a clinical trial application for RAG-01 in Australia. The mRNA drugs are approved for infectious disease (COVID-19) and metabolic disorders. Mina Therapeutics’ MTL-CEBPA is the first saRNA to advance into clinical trials globally.

Vaccines 102

Vaccines 102

STAT

SEPTEMBER 12, 2022

National Institutes of Health is launching a Phase 3 clinical trial to determine the efficacy of tecovirimat — the smallpox antiviral better known as TPOXX — for use in treating monkeypox, as current data on its effectiveness against the virus is limited , The Hill writes. The TPOXX was approved by the U.S.

218

218

Express Pharma

MARCH 21, 2024

The day aims to raise awareness about the devastating health, social, and economic consequences of the disease. It is one of the leading causes of death from an infectious agent, and therefore, efforts are very much needed to eradicate the infection. This year’s theme – ‘Yes, we can end TB!’- TB remains a global pandemic, with 1.8

Vaccines 102

Vaccines 102

ID Stewardship

MAY 21, 2023

On this webpage, a list of antimicrobial stewardship and infectious diseases conferences and meetings is provided. BCPS, BCIDP Article Posted May 2023 There are many infectious diseases conferences and meetings that take place around the world each year. List Composed By: Timothy P. Gauthier, Pharm.D.,

Chemotherapy 52

Chemotherapy 52

Pharmacy Is Right For Me

AUGUST 10, 2022

Dr. Brown is the National Field Director for Janssen Infectious Diseases & Vaccines. Medical Affairs, Infectious Diseases, where I worked on both the HCV and HIV clinical teams, leading efforts on research trials, as well as product launch activities. Today we’re excited to spotlight Kimberley Brown, Pharm.D.!

Vaccines 130

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Development 130

Pharmacy Times

MAY 6, 2024

Merck presented results from the STRIDE-10 phase 3 trial at the 34th European Society of Clinical Microbiology and Infectious Diseases in Barcelona, Spain.

Immunity 26

Immunity Immunization 26

Express Pharma

APRIL 17, 2023

Bugworks Research will present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark. The ECCMID conference is a global forum for infectious diseases and clinical microbiology.

52

52

Pharmafile

MARCH 22, 2023

Published date: 22/03/2023 Summary: VANCOUVER, British Columbia & LONDON, March 22, 2023 – AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV).

52

52

Pharmaceutical Technology

MARCH 28, 2023

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. In its FY 2022 report, BioNTech has identified herpes simplex virus (HSV), malaria, and shingles as disease targets.

Vaccines 110

Vaccines 110

Pharmaceutical Business Review

JANUARY 25, 2024

The site is strategically equipped to advance the clinical development of genetic medicine programmes. Among these is Covigenix, a Covid-19 booster vaccine, and future candidates targeting rare disease, eye and ophthalmic conditions, oncology, and other infectious diseases.

Vaccines 104

Vaccines 104

Board Vitals - Pharmacist

JANUARY 24, 2024

Cardiovascular Disease In 2023, the pass rate for first-time test takers remained level, with 86% of takers passing the exam. Infectious Disease The Infectious Disease board exam saw a slight increase in pass rates, going from 94% in 2022 to 96% in 2023. Don’t become complacent.

101

101

Pharmacy Times

OCTOBER 27, 2023

With a new administration protocol created specifically for the routine clinic, infectious disease physicians can treat recurrent clostridioides difficile infection in less than 3 weeks.

55

55

ID Stewardship

MARCH 23, 2023

In this article three infectious diseases pharmacists discuss the cross-roads of antimicrobial resistance and microbiology laboratory, reflecting on a recent Twitter chat on the topic. AMR is scary and means many things to different people.

Doctor of Pharmacy 62

Doctor of Pharmacy Hospitals Communication 62

European Pharmaceutical Review

APRIL 18, 2024

More about the EAGLE-1 trial for the antibiotic gepotidacin The global phase III clinical programme for gepotidacin in adults and adolescents involved three clinical trials. GSK shared that the safety and tolerability profile of gepotidacin in this trial was consistent with data seen in Phase I and II trials.

100

100

Express Pharma

JANUARY 23, 2024

The Serum Institute of India (SII), is joining a CEPI network of vaccine producers in the Global South to support more rapid, agile, and equitable responses to future public health disease outbreaks. With CEPI’s funding, SII will also support the development, stockpiling and licensure of new vaccines against CEPI’s priority pathogens.

Vaccines 101

Vaccines 101

Pharmaceutical Commerce

FEBRUARY 7, 2023

The new $43M plasmid manufacturing facility will support both clinical and commercial production in the cancer and infectious disease spaces.

52

52

European Pharmaceutical Review

MAY 19, 2023

The ATTACK trial was done at 59 clinical sites in 16 countries with adults aged 18 years or older. Mortality due to multiple causes after 28 days was 12 of 63 (19 percent) in the sulbactam–durlobactam group. In the colistin group, the mortality was 32 percent.

Hospitals 103

Hospitals Medical Schools 103

European Pharmaceutical Review

JUNE 27, 2022

The European Commission (EC) has launched the Healthier Together: EU Non-communicable diseases (NCDs) initiative to support EU Member States in reducing the burden of NCDs by addressing the leading causes of avoidable premature death in Europe and improving citizens’ health and well-being. Europe’s Healthier Together initiative.

Vaccines 94

Vaccines Communication Documentation Compounding 94

European Pharmaceutical Review

NOVEMBER 29, 2022

National Institute for Health and Care Research (NIHR)’s Clinical Research Network. It will also involve experts in infectious diseases and virology who will monitor the flu virus to see if it becomes resistant to the anti-viral drugs tested in the trial.

Hospitals 99

Hospitals Vaccines 99

ID Stewardship

DECEMBER 1, 2022

In this article a pharmacist with advanced training and experience in infectious diseases discusses five things pharmacists should know about ventilator associated pneumonia (VAP). Let’s start by simply defining this disease: VAP is pneumonia that occurs in patients that have been on mechanical ventilation for more than 48 hours.

Hospitals 127

Hospitals 127

Pharmacy Is Right For Me

DECEMBER 14, 2023

Dr. Small is a pediatric clinical pharmacist specialist but if you had asked him years earlier, he would not have thought that he would end up working with children, “Pediatrics was actually the only specialty I intentionally avoided in pharmacy school due to my fear that I would make a medication error and harm a child.”

Inpatient 162

Inpatient Hospitals 162

Pharmafile

MARCH 31, 2023

All will continue to work with partners in order to move forward with preclinical and clinical development in the infectious diseases and oncology fields. Japan-based NEC Corporation has announced that it is realigning its subsidiaries in order to streamline its AI drug development services. read more

Drug Development 52

Drug Development Communication 52

European Pharmaceutical Review

JANUARY 19, 2024

According to GlobalData, with demonstrated efficacy against carbapenem-resistant Acinetobacter Baumanni (CRAB), Roche’s zosurabalpin “has the potential to treat lethal hospital infection,” Anaelle Tannen, Infectious Disease Analyst at GlobalData explained. An example is Fetroja (cefiderocol sulfate tosylate).

Hospitals 93

Hospitals 93

Express Pharma

MAY 26, 2023

Eisai has conducted a Phase II clinical trial of its in-house developed agent E1224 (generic name: fosravuconazole) in Sudan for the treatment of mycetoma in partnership with the non-profit organisation Drugs for Neglected Diseases initiative (DNDi).

Vaccines 95

Vaccines 95

Express Pharma

JUNE 15, 2023

Some candidates have already reached clinical development. The first mRNA-based universal vaccine, H1ssF-3928 mRNA-LNP, which was designed by the Vaccine Research Centre (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), has also recently advanced to Phase I clinical development in the US.

Vaccines 93

Vaccines Immunity Immunization Hospitals 93

European Pharmaceutical Review

APRIL 28, 2023

The initiative will help to improve clinical decision-making regarding antimicrobial use and also inform practices and guidelines for prescribers, users and policymakers. Researchers will work to build knowledge in optimal antibiotics use, improved access to effective treatment and better prevention and treatment of bacterial infections.

93

93

Pharmaceutical Technology

JUNE 24, 2022

GlaxoSmithKline (GSK) has announced plans to invest $1.2bn (£1bn) over a decade to expedite research and development (R&D) for infectious diseases in lower-income countries. These ailments are said to account for over 60% of the disease burden in several lower-income countries.

Vaccines 59

Vaccines 59

European Pharmaceutical Review

MARCH 26, 2024

“We are excited to announce our fourth infectious disease vaccine programme with positive Phase III data,” stated Stéphane Bancel, Chief Executive Officer of Moderna. These findings were based on data comparing the treatment to mRNA-1273.222 (Spikevax ® ), Moderna’s licensed vaccine for the condition.

Vaccines 94

Vaccines Immunity Immunization 94

pharmaphorum

JULY 7, 2022

In the second of a three-part series, Ben Hargreaves looks at the importance of early-stage research into various emerging infectious disease threats and how it saved precious time in the work to develop a working vaccine during the current pandemic. Research defence.

Vaccines 103

Vaccines Immunity Immunization 103

pharmaphorum

JANUARY 6, 2023

The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim. It will also cover some infectious disease targets. ” Image via @BioNTech_Group twitter.

Vaccines 109

Vaccines Immunity Immunization Drug Development 109

ID Stewardship

MAY 13, 2023

In this article an infectious diseases pharmacists discusses the MAD-ID conference, which is known as The Antimicrobial Stewardship Meeting, Making A Difference In Infectious Diseases (MAD-ID). Scroll to the bottom of this post for a list of infectious diseases meetings that have been sourced from Twitter.

Communication 52

Communication 52

Pharmaceutical Business Review

JANUARY 31, 2024

With a combined annual death toll of 139,000 in the US and European Union, it is the third deadliest cancer in these regions. The five-year relative survival rate for advanced stages of the disease is a mere 3%, highlighting the urgent need for more effective treatments.

Immunity 59

Immunity Immunization Vaccines 59

pharmaphorum

MARCH 2, 2021

With pandemic vaccines now launching at record speeds, the first Genetic Vaccine Development for Infectious Diseases Summit will focus on overcoming the translational and clinical challenges of developing genetic vaccines targeting infectious diseases, including Influenza , Lassa Fever , Ebola , MERS , HIV , Zika , and COVID-19.

Vaccines 52

Vaccines 52